%0 Journal Article
%A Tomsitz, Dirk
%A Livingstone, Elisabeth
%A Loquai, Carmen
%A Kaatz, Martin
%A Leiter, Ulrike
%A Schilling, Bastian
%A Terheyden, Patrick
%A Hassel, Jessica
%A Sachse, Michael
%A Ulrich, Jens
%A Dippel, Edgar
%A Meiss, Frank
%A Pföhler, Claudia
%A Kreuter, Alexander
%A Herbst, Rudolf
%A Weichenthal, Michael
%A Zimmer, Lisa
%A Meier, Friedegund
%A Rauschenberg, Ricarda
%A Mohr, Peter
%A Brunnert, Fiona
%A von Wasielewski, Imke
%A Gutzmer, Ralf
%A Schadendorf, Dirk
%A Berking, Carola
%A Ugurel, Selma
%A Heinzerling, Lucie
%T Early termination does not negatively impact the outcome of adjuvant immunotherapy in melanoma.
%J Journal of the European Academy of Dermatology and Venereology
%V nn
%@ 0926-9959
%C Oxford [u.a.]
%I Wiley-Blackwell
%M DKFZ-2025-00603
%P nn
%D 2025
%Z epub
%X Adjuvant treatment with anti-PD1 antibodies has been shown to effectively reduce the risk of recurrence in patients with resected metastatic melanoma. Whether a full 12-month duration of treatment is needed to achieve full clinical benefit is not known. This study investigated the survival outcome depending on the duration of adjuvant anti-PD1 therapy.From the prospective multicentre real-world skin cancer registry ADOREG data of 620 patients who finished adjuvant treatment with nivolumab or pembrolizumab for AJCCv8 stage III/IV resected melanoma was analyzed. Recurrence-free survival (RFS) and overall survival (OS) were compared between patients with regular treatment duration (52 ± 4 weeks; n = 229) and no disease recurrence during therapy (A1) and patients with a premature end of treatment (<48 weeks; n = 214, B). Patients with disease recurrence during adjuvant treatment were included in cohort A2.The median duration of follow-up was 26.0 months [interquartile range (IQR) 18.0-34.0] in group A1 [median treatment duration 51.3 weeks (IQR 50.0-52.1) and 19.0 months (IQR 13.0-29.0)] in group B [median treatment duration 22.2 weeks (IQR 10.0-34.8)]. Reasons for early discontinuation were treatment-related side effects in 45.3
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40119686
%R 10.1111/jdv.20650
%U https://inrepo02.dkfz.de/record/300103